CD274 and neoplasm: Among patients with a combined positive score (CPS; the number of PD-L1 positive cells including tumor, lymphocytes and macrophages, in relation to total tumor cells) for tumor and immune cell PD-L1-expression of at least 1, median OS was 8.7 months (95% CI 6.9–11.4) with pembrolizumab versus 7.1 months (5·7–8·3) with standard treatments (HR 0.74; 95% CI: 0.58–0.93, p = 0.0070).